SCHEMBL6742318

SCHEMBL6742318

COc1cc(CNc2nc(C)nc(C)c2Cl)ccc1OCc1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MRGPRX1 Q96LB2 3/20 0.52
KMT2A Q03164 4/20 0.51
MEN1 O00255 3/20 0.51
LMNA P02545 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
KDM4E B2RXH2 2/20 0.51
ALDH1A1 P00352 2/20 0.51
TP53 P04637 2/20 0.51
L3MBTL1 Q9Y468 2/20 0.51
HTT P42858 1/20 0.51
F2 P00734 1/20 0.51
F10 P00742 1/20 0.51
PRSS1 P07477 1/20 0.51
F7 P08709 1/20 0.51
PLK1 P53350 1/20 0.50
GAA P10253 1/20 0.50
MAPT P10636 1/20 0.50
ALOX12 P18054 1/20 0.50
MAPK1 P28482 1/20 0.50
NLRP3 Q96P20 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6739846 0.96 SMN1; SMN2 (0.56) MRGPRX1KMT2AMEN1LMNASMN1; SMN2
SCHEMBL6742495 0.88 KMT2A (0.44) MRGPRX1KMT2AMEN1LMNASMN1; SMN2
SCHEMBL6740329 0.87 KMT2A (0.46) MRGPRX1KMT2AMEN1LMNASMN1; SMN2
SCHEMBL6742315 0.87 KMT2A (0.46) MRGPRX1KMT2AMEN1LMNASMN1; SMN2
SCHEMBL6739837 0.86 MEN1 (0.45) MRGPRX1KMT2AMEN1LMNASMN1; SMN2
SCHEMBL6741858 0.84 KMT2A (0.59) KMT2AMEN1LMNASMN1; SMN2KDM4E
SCHEMBL6740580 0.82 BCHE (0.51) KMT2AMEN1SMN1; SMN2KDM4EALDH1A1
SCHEMBL15685008 0.82 F2 (0.51) MRGPRX1KMT2AMEN1TP53F2
SCHEMBL6742014 0.82 TSHR (0.48) KMT2AMEN1GAAMAPK1BCHE
SCHEMBL6882105 0.81 GCK (0.41) KMT2AMEN1LMNASMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6818642-B2 CAMPYLOBACTER INFECTION TREATMENT ALTANA PHARMA AG (DE) 2004-11-16 US disclosed
US-20040152714-A1 Benzylaminopyrimidines ALTANA PHARMA AG (DE) 2004-08-05 US disclosed
EP-1395594-A1 NEW BENZYLAMINOPYRIMIDINES Byk Gulden Lomberg Chemische Fabrik GmbH (DE) 2004-03-10 EP disclosed
WO-2002094832-A1 NEW BENZYLAMINOPYRIMIDINES ALTANA PHARMA AG (DE) 2002-11-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152714-A1 Benzylaminopyrimidines DPYD, PGLS, TPMT MRGPRX1 3460/4885KMT2A 693/4885MEN1 2577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.